NovoCure (FRA:038) Accounts Payable & Accrued Expense : €170.5 Mil (As of Mar. 2025)

View and export this data going back to 2015. Start your Free Trial

What is NovoCure Accounts Payable & Accrued Expense?

NovoCure's quarterly accounts payable & accrued expense increased from Sep. 2024 (€160.1 Mil) to Dec. 2024 (€168.1 Mil) and increased from Dec. 2024 (€168.1 Mil) to Mar. 2025 (€170.5 Mil).

NovoCure's annual accounts payable & accrued expense increased from Dec. 2022 (€132.9 Mil) to Dec. 2023 (€141.7 Mil) and increased from Dec. 2023 (€141.7 Mil) to Dec. 2024 (€168.1 Mil).

NovoCure Accounts Payable & Accrued Expense Historical Data

The historical data trend for NovoCure's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovoCure Accounts Payable & Accrued Expense Chart

NovoCure Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

78.79

110.48

132.87

141.74

168.15

NovoCure Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															147.41	157.17	160.08	168.15	170.51

NovoCure Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

NovoCure Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NovoCure Ltd (FRA:038) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

NVCR:USA 038:Germany

Address

Grenville Street, No. 4 The Forum, Second Floor, St. Helier, JEY, JE2 4UF

Website

https://www.novocure.com

NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

NovoCure Headlines

No Headlines